Biopharmaceuticals Market Share Report, Growth Analysis 2028
生物制药市场预计将从 2022 年的 3299.6622 亿美元增长到 2028 年的 7008.7394 亿美元;预计 2022 年至 2028 年的复合年增长率为 13.4%。
癌症治疗应用的不断增长以及治疗罕见疾病的潜力是推动生物制药市场增长的一些因素 。
根据美国国家癌症研究所的报告,癌症是全球主要死亡原因之一。例如,2018年,全球新增癌症病例1810万例,癌症相关死亡人数950万例。到2040年,新增癌症病例预计将上升至2950万例,癌症相关死亡人数将上升至1640万例。美国卫生与公众服务部报告指出,每年每10万名男性和女性中,肺癌和支气管癌新发病例为52.0例。预计2022年新增肺癌和支气管癌病例数为236,740例,占所有新增癌症病例的12.3%。生物制药为控制如此高的癌症发病率提供了新的机会。基于对潜在生物机制和患者免疫系统在抗击癌症中的作用的理解,生物制药研究人员正在生产用于治疗不同类型癌症的新药。这些疗法包括CAR-T 细胞疗法、免疫检查点抑制剂和个性化药物,旨在治疗导致特定癌症状况的基因缺陷。美国药品研究与制造商协会 (PhRMA) 的一份报告显示,美国食品药品管理局 (FDA) 已批准六种 CAR-T 疗法,用于治疗多种癌症类型,包括儿童癌症病例。此外,PhRMA 报告显示,其他治疗方法也已获得批准,例如具有转化多种癌症潜力的 mRNA。例如,2023 年 2 月,Moderna, Inc. 和 Merck 研发的个性化 mRNA 癌症疫苗 mRNA-4157/V940 与 KEYTRUDA 联合使用,被美国食品药品管理局认定为突破性疗法。此外,目前有 1,300 多种用于治疗各种癌症的药物和疫苗正在临床试验中或等待 FDA 批准。这些包括免疫疗法(单克隆抗体和 CAR-T)、靶向癌症的基因编辑、溶瘤病毒疗法以及针对特定癌细胞而不损害正常细胞的抗体-药物偶联物 (ADC)。
因此,全球癌症发病率的上升导致了对安全、有效、高效的诊断系统(如生物制药)的需求。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
生物制药市场:
复合年增长率(2022 - 2028)13.4%- 2022 年市场规模
3299.7 亿美元 - 2028 年市场规模
7008.7 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- 安进公司
- 艾伯维公司(AbbVie Inc.)
- 礼来公司
- 百时美施贵宝公司
- 强生公司
- 赛默飞世尔科技公司
- AGC Biologics 公司
- 龙沙集团
- 药明生物
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 单克隆抗体
- 重组疫苗
- 传统疫苗
- 重组生长因子
- 纯化蛋白质
- 重组蛋白
- 重组激素
- 重组酶
- 细胞和基因疗法
- 细胞因子/干扰素/白细胞介素
- 其他的
- 肿瘤学
- 炎症和传染病
- 自身免疫性疾病
- 代谢紊乱
- 激素失调和生长障碍
- 心血管疾病
- 神经系统疾病
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
应用领域洞察
根据应用,生物制药市场细分为肿瘤学、炎症和传染病、自身免疫性疾病、代谢紊乱、激素紊乱和生长障碍、心血管疾病、神经系统疾病等。肿瘤学领域在 2022 年占据了最大的市场份额。然而,炎症和传染病领域预计在预测期内将实现最高的复合年增长率。根据美国国立卫生研究院 (NIH) 的报告,癌症是一种复杂的侵袭性遗传疾病,在全球范围内造成大量死亡。例如,基于蛋白质的生物制药大大延长了数百万癌症患者的生命。此外,各大顶级公司开展了研究合作,以开发用于癌症治疗的新型疗法靶向蛋白质技术。例如,2022 年 4 月,Ubix Therapeutics 宣布与 SK Biopharmaceuticals 合作,通过 Ubix 的 Degraducer 技术开发用于癌症治疗的新化合物和药物。上述因素是该领域增长的原因,从而促进预测期内生物制药市场的增长。
在预测期内,北美很可能继续在生物制药市场占据主导地位。2022 年,美国在该地区占据了最大的市场份额。根据国际贸易管理局的报告,美国是最大的生物制药市场,约占全球生物制药市场的三分之一,拥有生物制药研发领域的先驱。此外,生物制药行业对美国经济的经济影响巨大。2018 年,超过 170 亿美元的生物制药出口来自在美国运营的大多数外资公司。此外,同年,这些多数外资公司在研发上花费了约 200 亿美元。
另一方面,预计亚太地区在预测期内将实现丰厚的增长。这是因为中国的生物制药行业正在经历巨大的转变,从以仿制药为中心转变为蓬勃发展的创新中心。此外,促进工业化和新型药物、高端医疗设备和技术的应用日益广泛,是中国生物制药市场增长的一些因素。
根据信息技术与创新基金会 (ITIF) 的报告,中国在创新方面取得了长足进步,赶超美国。此外,平均 36 项指标显示,中国与美国的差距缩小了 1.5 倍(竞争因素被确定并评估为实现公司战略目标的相对重要性)。此外,十年前,中国落后美国 80%;然而,由于创新、技术流入和国家主导的有利工业和贸易政策的巨大进步,到 2022 年,这一差距将达到 50%。此外,治疗罕见疾病的新产品获批进一步影响了中国的市场增长。例如,2022年3月,中国领先的生物制药公司北海康成药业有限公司宣布,台湾食品药物管理署(TFDA)已接受“CAN108 [马拉利昔巴特口服溶液(LIVMARLI TM)]”的新药申请/孤儿药注册(NDA/ODR),该药旨在治疗1岁以上患有阿拉吉欧综合征(ALGS)患者的胆汁淤积性瘙痒。
产品类型洞察
根据产品类型,生物制药市场细分为单克隆抗体、重组疫苗、常规疫苗、重组生长因子、纯化蛋白、重组蛋白、重组激素、重组酶、细胞和基因疗法、细胞因子/干扰素/白细胞介素和其他(基于 mRNA 的疗法等)。单克隆抗体细分市场在 2022 年占据最大市场份额,预计在预测期内将实现显着的复合年增长率。单克隆抗体 (mAB) 处于生物制品市场的前列,并将继续通过提供针对免疫肿瘤学和免疫疗法的创新治疗解决方案引领生物制药市场的资源投资。mAB 可治疗多种疾病,例如癌症、器官移植排斥、炎症和自身免疫性疾病、过敏、感染、COVID-19、骨质疏松症、眼部疾病、偏头痛、高胆固醇和神经系统疾病。有许多不同的 mAB 用于治疗癌症。它们以不同的方式杀死或阻止癌细胞生长。它们的名称都在通用名末尾包含“mab”——例如曲妥珠单抗 (Herceptin) 和利妥昔单抗 (Mabthera)。自从第一种含有单克隆抗体的药物获批用于人类以来,美国食品药品管理局 (FDA) 对单克隆抗体疗法的批准数量有所增加。单克隆抗体的一个主要优点是它们已成功用于制造治疗某些疾病(例如某些癌症)的药物。单克隆抗体的另一个优点是它们比其他治疗方法更准确。这提高了疗效并可以减少一些副作用。单克隆抗体的质量是所有生产批次的标准,这对于治疗用途和诊断都很重要。上述因素是该细分市场增长的原因,从而在预测期内推动生物制药市场的发展。
在生物制药市场运营的公司采用产品创新战略来满足全球不断变化的客户需求,从而使他们能够在全球市场上保持自己的品牌名称。
生物制药市场报告范围
报告属性 | 细节 |
---|---|
2022 年市场规模 | 3299.7亿美元 |
2028 年市场规模 | 7008.7亿美元 |
全球复合年增长率(2022 - 2028) | 13.4% |
历史数据 | 2020-2021 |
预测期 | 2023-2028 |
涵盖的领域 | 按产品类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
生物制药市场 – 细分
根据产品类型,生物制药市场细分为单克隆抗体、重组疫苗、常规疫苗、重组生长因子、纯化蛋白、重组蛋白、重组激素、重组酶、细胞和基因疗法、细胞因子/干扰素/白细胞介素等。根据应用,市场细分为肿瘤学、炎症和传染病、自身免疫性疾病、代谢紊乱、激素紊乱和生长障碍、心血管疾病、神经系统疾病等。根据地理位置,市场主要细分为北美、欧洲、亚太地区 (APAC)、中东和非洲 (MEA) 以及南美洲和中美洲。北美市场进一步细分为美国、加拿大和墨西哥。欧洲生物制药市场细分为法国、德国、英国、西班牙、意大利和欧洲其他地区。亚太地区市场进一步细分为中国、印度、日本、澳大利亚、韩国和亚太地区其他地区。中东和非洲地区的生物制药市场细分为沙特阿拉伯、阿联酋、南非和中东和非洲其他地区。南美洲和中美洲市场进一步细分为巴西、阿根廷和南美洲和中美洲其他地区。
生物制药市场的一些领先公司包括安进公司、艾伯维公司、礼来公司、百时美施贵宝公司、强生公司、赛默飞世尔科技公司、AGC Biologics AS、龙沙集团、药明生物技术公司和勃林格殷格翰国际有限公司。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global biopharmaceuticals market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the biopharmaceuticals market in 2022. With several North American market players focusing on research and development activities in the field of imaging technology, the regional market for biopharmaceuticals market is likely to propel in North America region during the forecast period.
Eli Lilly and Co and Amgen Inc are the top two companies that hold huge market shares in the biopharmaceuticals market.
The biopharmaceuticals market majorly consists of the players such Amgen Inc, AbbVie Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, Johnson & Johnson, Thermo Fisher Scientific Inc, AGC Biologics AS, Lonza Group AG, WuXi Biologics Inc, Boehringer Ingelheim International GmbH amongst others.
The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 13.4%.
The monoclonal antibodies segment held the largest share of the market in the global biopharmaceuticals market and held the market share of 48.42% in 2022.
Biopharmaceuticals are complex medicines that are manufactured by extracting proteins and nucleic acids directly from biological sources using biotechnology. Most biopharmaceuticals are pharmaceutical products that are made from living organisms; transgenic organisms are genetically modified plants and animals, and this process is used to produce biopharmaceuticals; nevertheless, it is a controversial technology still in the testing phase.
Key factors that are driving the growth of this market are rising application in cancer therapeutics and potential to treat rare diseases are expected to boost the market growth for the biopharmaceuticals over the years.
The List of Companies - Biopharmaceuticals Market
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and Co
- Bristol-Myers Squibb Co
- Johnson & Johnson
- Thermo Fisher Scientific Inc
- AGC Biologics AS
- Lonza Group AG
- WuXi Biologics Inc
- Boehringer Ingelheim International GmbH.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.